Gene · 634
Papers3,222
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
721 to 740 of 3,222
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. | Cancers (Basel) | 2022 | 35804849 | PubTator, text mining | PubMed |
| Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. | Cancers (Basel) | 2022 | 35804808 | PubTator, text mining | PubMed |
| Identification of Two Subtypes and Prognostic Characteristics of Lung Adenocarcinoma Based on Pentose Phosphate Metabolic Pathway-Related Long Non-coding RNAs. | Front Public Health | 2022 | 35801241 | PubTator, text mining | PubMed |
| Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response. | Cancer Drug Resist | 2022 | 35800370 | PubTator, text mining | PubMed |
| A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection. | Sci Rep | 2022 | 35794133 | PubTator, text mining | PubMed |
| Systematic review of host genomic biomarkers of invasive bacterial disease: Distinguishing bacterial from non-bacterial causes of acute febrile illness. | EBioMedicine | 2022 | 35792524 | PubTator, text mining | PubMed |
| Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1. | Nat Chem Biol | 2022 | 35788181 | PubTator, text mining | PubMed |
| Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. | Expert Rev Anticancer Ther | 2022 | 35786142 | PubTator, text mining | PubMed |
| Reversal of obesity development in Ceacam1-/- male mice by bone marrow transplantation or introduction of the human CEACAM1 gene. | Obesity (Silver Spring) | 2022 | 35785480 | PubTator, text mining | PubMed |
| Chitosan/Sodium Alginate/Velvet Antler Blood Peptides Hydrogel Promoted Wound Healing by Regulating PI3K/AKT/mTOR and SIRT1/NF-κB Pathways. | Front Pharmacol | 2022 | 35784748 | PubTator, text mining | PubMed |
| The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes. | Front Immunol | 2022 | 35784290 | PubTator, text mining | PubMed |
| Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. | Front Med (Lausanne) | 2022 | 35774996 | PubTator, text mining | PubMed |
| Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. | J Immunother Cancer | 2022 | 35764368 | PubTator, text mining | PubMed |
| Precision medicine: how multiomics will shape the future of inflammatory bowel disease? | Curr Opin Gastroenterol | 2022 | 35762697 | PubTator, text mining | PubMed |
Investigation of the Disparities in Ultrasound Imaging Features of miR-323, miR-409-3p, and VEGF Expression Scales in Different Clinicopathological Features of Prostate Carcinoma and Their Correlation with Prognosis. | Biomed Res Int | 2022 | 35761975 | PubTator, text mining | PubMed |
| A Novel Prognostic Signature Based on Glioma Essential Ferroptosis-Related Genes Predicts Clinical Outcomes and Indicates Treatment in Glioma. | Front Oncol | 2022 | 35756689 | PubTator, text mining | PubMed |
| Preparation of a "Branch-Fruit" structure chitosan nanofiber physical hydrogels with high mechanical strength and pH-responsive controlled drug release properties. | RSC Adv | 2022 | 35755578 | PubTator, text mining | PubMed |
| Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling. | Cell Commun Signal | 2022 | 35752798 | PubTator, text mining | PubMed |
| Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo. | Front Immunol | 2022 | 35747143 | PubTator, text mining | PubMed |
| Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. | Molecules | 2022 | 35744922 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/634/papers?page=37